Literature DB >> 27940027

Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.

Sunwen Chou1.   

Abstract

Human cytomegalovirus UL54 DNA polymerase gene mutations that confer foscarnet resistance in clinical practice typically cluster in the amino terminal 2, palm and finger domains. Exposure to foscarnet in cell culture selected for mutations elsewhere in UL54, including amino acid substitutions S290R in the amino terminal 1 domain and E951D in the palm 2 domain. These are newly confirmed to confer foscarnet resistance and slightly decreased ganciclovir susceptibility. Other emergent substitutions N495K, T552N and T838A are known to confer foscarnet resistance, while additional ones Q783R and V798A only slightly affected susceptibility. An expanded set of domains is involved in foscarnet resistance and its genotypic diagnosis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27940027      PMCID: PMC5209250          DOI: 10.1016/j.antiviral.2016.12.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  22 in total

1.  Crystal structure of the herpes simplex virus 1 DNA polymerase.

Authors:  Shenping Liu; John D Knafels; Jeanne S Chang; Gregory A Waszak; Eric T Baldwin; Martin R Deibel; Darrell R Thomsen; Fred L Homa; Peter A Wells; Monica C Tory; Roger A Poorman; Hua Gao; Xiayang Qiu; Andrew P Seddon
Journal:  J Biol Chem       Date:  2006-04-24       Impact factor: 5.157

2.  Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.

Authors:  Sunwen Chou; Laura C Van Wechel; Heather M Lichy; Gail I Marousek
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.

Authors:  Sunwen Chou; Guy Boivin; Jane Ives; Robert Elston
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

4.  Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.

Authors:  Christian Gilbert; Arezki Azzi; Nathalie Goyette; Sheng-Xiang Lin; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

5.  Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase.

Authors:  Karl E Zahn; Egor P Tchesnokov; Matthias Götte; Sylvie Doublié
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

6.  Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.

Authors:  D Andouard; M-C Mazeron; G Ligat; A Couvreux; C Pouteil-Noble; R Cahen; Y Yasdanpanah; M Deering; N Viget; S Alain; S Hantz
Journal:  Antiviral Res       Date:  2016-02-10       Impact factor: 5.970

7.  Cytomegalovirus antiviral resistance: characterization of results from clinical specimens.

Authors:  S Kleiboeker; J Nutt; B Schindel; J Dannehl; J Hester
Journal:  Transpl Infect Dis       Date:  2014-06-05       Impact factor: 2.228

Review 8.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

9.  PDGF receptor-α does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway.

Authors:  Adam L Vanarsdall; Todd W Wisner; Hetian Lei; Andrius Kazlauskas; David C Johnson
Journal:  PLoS Pathog       Date:  2012-09-13       Impact factor: 6.823

Review 10.  Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.

Authors:  D Topalis; S Gillemot; R Snoeck; G Andrei
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

View more
  9 in total

1.  Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.

Authors:  Sunwen Chou; Ronald J Ercolani; Adam L Vanarsdall
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

2.  New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir.

Authors:  Sunwen Chou; L Elizabeth Satterwhite; Ronald J Ercolani
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.

Authors:  Ifeoma N Ude; Steven Yeh; Jessica G Shantha
Journal:  Ann Eye Sci       Date:  2022-03

4.  Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.

Authors:  Lauren Cherrier; Aasya Nasar; Kellie J Goodlet; Michael D Nailor; Sofya Tokman; Sunwen Chou
Journal:  Am J Transplant       Date:  2018-10-29       Impact factor: 8.086

5.  Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.

Authors:  Sunwen Chou; Ronald J Ercolani; Katayoun Derakhchan
Journal:  Antiviral Res       Date:  2018-07-21       Impact factor: 5.970

Review 6.  Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2020-01-12       Impact factor: 5.970

7.  Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2021-09-21       Impact factor: 5.970

8.  An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness.

Authors:  Erika Trompet; Arturo Temblador; Sarah Gillemot; Dimitrios Topalis; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

9.  Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection.

Authors:  Sunwen Chou; Kening Song; Jingyang Wu; Tien Bo; Clyde Crumpacker
Journal:  J Infect Dis       Date:  2020-07-29       Impact factor: 7.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.